Pergola breaks down findings from a phase 2 trial of OLC for managing hyperphosphatemia in patients with chronic kidney disease receiving dialysis.
Pablo Pergola, MD, PhD
Advertisement
Pablo Pergola, MD, PhD, is the research director of the Clinical Advancement Center at Renal Associates PA.
Articles by Pablo Pergola, MD, PhD
Pergola describes the shortcomings of current phosphate binders and what benefits OLC may offer for hyperphosphatemia in patients with CKD on dialysis.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
SimpleScreen CRC Blood Test Meets Endpoints in Clinical Validation Study
2
Liver Lineup: Bepirovirsen and the Push Toward Functional Cure in Hepatitis B
3
Eplontersen Misses Primary Endpoint in Phase 3 ATTR-CM Trial
4
Biologic Therapy for Asthma and COPD: Real-World Perspectives From APPs
5